Synergistic tumorcidal response induced by histamine

A technology of histamine and application, which can be used in antitumor drugs, medical preparations containing active ingredients, drug combinations, etc., and can solve problems such as poor absorption and low affinity

Inactive Publication Date: 2002-03-27
MAXIM PHARMA INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, low-level expression of targeted tumor-associated antigens, low-affinity mAbs, ineffective radionuclides, non-specific toxicity of antibody conjugates, and poor tumor uptake of therapeutic drugs limit the use of antibody-based therapies such as immunotoxins, immune radionuclides, immune Complex Conjugated Pairs of Coordination Compounds and Receptor-Specific Antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Five acute myeloid leukemia (AML) patients in remission were treated with histamine dihydrochloride diluted in sterile sodium chloride solution. Histamine was injected at separate subcutaneous injection sites in the morning and evening over a 21-day period. Histamine was administered subcutaneously using a 1 ml syringe containing 0.1 mg / ml histamine. Histamine therapy was given twice a day (morning and evening) at a dose of 0.4-0.7 mg histamine per injection (ie a total daily dose of histamine of 0.8-1.4 mg / day).

[0036] Peripheral venous blood samples were taken in 10 ml heparinized tubes before starting treatment and weekly thereafter. Samples were taken at least 8 hours after the last histamine injection. Whole blood samples were analyzed for histamine concentration by using a double antibody radioimmunoassay kit from Bionerica, Inc., Newport Beach, California 92663 (Cat. No. 1051). The assay was performed according to the manufacturer's instructions supplied wit...

Embodiment 2

[0042] A synergistic tumor-destroying effect was obtained by administering histamine before, during and after surgical removal of the prostate tumor. Accordingly, a pharmaceutically acceptable form of histamine dissolved in a sterile vehicle solution was administered subcutaneously to prostate cancer patients for one week prior to surgery (0.5-2.0 mg per day). Following treatment, tumors were surgically resected when circulating blood histamine levels rose to at least 0.2 [mu]M.

[0043] Once the tumor is removed, circulating blood histamine levels are maintained at least about 0.2 [mu]M until a complete therapeutic response is observed. According to conventional methods, the level of PSA antigen in patients was detected at different times to evaluate the destructive effect on tumors. By employing the methods disclosed in this example, synergistic tumor destruction was observed and prostate cancer was effectively treated.

[0044] Cancer Therapy Combining His...

Embodiment 3

[0047] A synergistic tumor-destroying effect was obtained by administering histamine before, during and after radiation therapy of prostate tumors. Accordingly, a pharmaceutically acceptable form of histamine dissolved in a sterile carrier solution was administered subcutaneously to a prostate cancer patient for one week prior to radiation therapy (0.5-2.0 mg per day). Following treatment, when circulating blood histamine levels had increased to at least 0.2 [mu]M, the tumors were subjected to external teleradiation (60-70 Gy).

[0048] Once the tumor is irradiated, the circulating blood histamine level is maintained at at least about 0.2 [mu]M until a complete therapeutic response is observed, and tumor destruction is assessed by routinely measuring the patient's PSA antigen level at various times. By using the methods disclosed in this example, synergistic tumor destruction was observed and prostate cancer was effectively treated.

[0049] Cancer Therapy Comb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.

Description

field of invention [0001] The present invention relates to methods of treating cancer wherein histamine is administered in combination with other cancer therapies. The cancer therapy includes surgery, radiation therapy, immunotherapy, administration of drugs that enhance the patient's humoral immune response, or any combination thereof. Background of the invention [0002] Despite tremendous advances in cancer treatment over the past few years, current cancer therapies are still unable to cure many types of cancer. The questions facing researchers and clinicians are many. Some tumors are unresectable or do not respond to radiation or chemotherapy or a combination of these methods. Moreover, the severe pathogenicity often associated with these therapies has led many to seek entirely new tumor therapies that are more specific in destroying cancer cells and less toxic to normal cells. Various efforts to boost immune responses against tumors by immunizing c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/203A61K31/417A61K45/00A61K33/18A61K35/12A61K38/00A61K39/12A61K39/35A61K39/395A61K41/00A61K51/00A61P35/00A61P35/02
CPCA61K39/395A61K41/0038A61K31/417A61P35/00A61P35/02A61K31/415A61K2300/00
Inventor K·R·格尔森K·赫尔斯特兰德S·赫尔莫德松
Owner MAXIM PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap